Cross-priming dendritic cells and CD8+ T cells represent potential novel therapeutic targets to prevent postischemic immunopathology and heart failure.
Activation of cytotoxic CD8+ T cells by cross-priming DC contributes to exacerbation of postischemic inflammatory damage of the myocardium and corresponding decline in cardiac function. Importantly, this provides novel therapeutic targets to prevent postischemic immunopathology and heart failure.
Forte et al. (Thu,) studied this question.